Assessment of the Interi Manifold in Implant-Based Breast Reconstruction

Recruiting now · Not applicable

Conditions studied: Mastectomy, Implant Based Breast Reconstruction

In brief

Patients with breast cancer that elect to undergo implant-based breast reconstruction (IBBR) often require the placement of a surgical drain. Surgical drains are used to manage dead space and prevent seroma formation or accumulation of fluid within the surgical field postoperatively. The most frequently used drain is a Jackson-Pratt (JP) drain, which is limited by poor surgical site coverage and low capacity, leading to inconsistent suction and prolonged time that a drain is left in place. The Interi Drain system is a novel, multi-branched manifold with a proprietary suction system that provides consistent suction and addresses many of the shortcoming of JP drains. The purpose of this study is to compare the Interi system to standard JP drains across outcomes including number of surgical drain sites, complication rates, time to drain removal, time to initiate tissue expansion, total fluid volume drained, and patient satisfaction.

Key facts

Study ID

NCT05975359

Run by

Stanford University

People needed

20

Starts

2023-10-05

Expected to finish

2026-09-01

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Breast cancer diagnosis (any form) or Genetic mutation with presence of breast mass.
• Indication for bilateral mastectomy
• Plan for immediate, implant-based pre-pectoral breast reconstruction using an acellular dermal matrix
• Age 18 - 65
• Female Sex
• Ability to understand and the willingness to personally sign the written IRB-approved informed consent document (English language).

You may not qualify if…

• Have a prior history of radiation to the breast or planned radiotherapy to the breast within the first year post-operatively.
• Are enrolled in another study that requires the concomitant use of any investigational product during the study period that the Principal Investigator believes will interfere with study endpoints.
• Have received oncologic chemotherapy within the past 21 days or planned within the time fame of the study intervention. Have received antiplatelet therapy (other than aspirin) and/ or other anticoagulation therapy in the past 60 days.
• Are a smoker or use illicit drugs.
• Any prior allergic reaction to Teflon.
• Are pregnant or nursing.
• Are undergoing a delayed reconstruction following mastectomy.
• HIV infection, active UTI infection, or other active infection.
• Those requiring more than one Manifold for fluid removal per breast will be excluded.

Where it is running

• Stanford Hospital and Clinics — Palo Alto, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.